Related Experiment Video
Updated: May 28, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Ruthenium-106 brachytherapy.
1Department of Ophthalmology, Jonas Friedenwald Professor of Ophthalmic Research, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Developments in Ophthalmology
|November 2, 2011
Summary
Ruthenium-106 (Ru-106) brachytherapy is a common treatment for uveal melanoma, offering excellent local control and eye preservation. Its limited radiation penetration aids in better vision preservation and reduced damage to healthy eye tissues.
Area of Science:
- Ophthalmology
- Radiation Oncology
- Oncology
Background:
- Uveal melanoma is a primary intraocular malignancy.
- Brachytherapy is a frequently employed treatment modality for uveal melanoma.
- Ruthenium-106 (Ru-106) and Iodine-125 (I-125) are the most common isotopes used in brachytherapy for this condition.
Purpose of the Study:
- To review the application and efficacy of Ru-106 brachytherapy in treating uveal melanoma.
- To highlight the advantages of Ru-106 brachytherapy, particularly regarding vision preservation.
Main Methods:
- Review of clinical data and established practices for Ru-106 brachytherapy in uveal melanoma.
- Discussion of the physical properties of Ru-106 (beta emitter, limited penetration).
Main Results:
- Ru-106 brachytherapy demonstrates excellent local control rates for uveal melanoma.
- This method offers significant advantages in preserving vision and minimizing damage to healthy ocular structures due to its limited radiation range.
- Eccentric plaque placement can further protect critical structures like the macula and optic nerve.
Conclusions:
- Ru-106 brachytherapy is a highly effective and well-established treatment for uveal melanoma.
- Its favorable radiation characteristics make it a preferred option for ocular oncologists prioritizing vision preservation.
- Ru-106 can be used as a standalone treatment or in combination with other therapeutic modalities.
